Background-Myocarditis can cause dilated cardiomyopathy resulting in end-stage heart failure requiring advanced therapies. There is little contemporary information on the clinical progression, need for mechanical circulatory support, and outcomes of orthotopic heart transplantation of these patients. Despite higher allosensitization, patients with myocarditis had similar post-transplant rejection, retransplantation, and survival rates compared with other groups. Conclusions-Patients with the diagnosis of myocarditis listed for orthotopic heart transplantation are younger, sicker, and recover more frequently but require more biventricular mechanical circulatory support. Heart transplantation survival is comparable to that of patients with other types of heart failure. (Circ Heart Fail. 2016;9:e003259.
M
yocarditis is a multifactorial, lymphocyte-mediated inflammatory process of the heart most commonly caused by viruses. 1, 2 It has a variable clinical presentation and can be defined by either clinical or histopathologic criteria, making true incidence difficult to determine. 3, 4 It has been estimated that myocarditis accounts for 9% to 16% of nonischemic cardiomyopathies (NICM). 5 Heart failure (HF) related to myocarditis carries mortality rates of 56% at 4.3 years 6 and may lead to end-stage HF requiring advanced therapies. Heart transplantation (HT) is required in 1% to 8% of patients with myocarditis. 7 
See Clinical Perspective
Utilization of mechanical circulatory support (MCS) and HT outcomes in patients with myocarditis remain incompletely defined because most available information is derived from relatively small series and isolated case reports. [8] [9] [10] We, therefore, sought to use a large, contemporary, nationwide database to better understand the clinical characteristics, natural history, MCS needs, and HT outcomes of patients with end-stage HF from myocarditis listed for HT.
Methods

Data Source
Deidentified data were obtained from UNOS (United Network of Organ Sharing) and the Organ Procurement and Transplantation Network contracted with Health Resources and Services Administration. UNOS records compulsory transplantation information on listed patients in all centers across the United States. Data are collected at different time points: at listing, before transplantation, and continually after transplantation. The UNOS registry includes data on patient demographics, causes of cardiomyopathy, devices present, causes of removal from wait list, hemodynamics, and other peritransplantation and long-term data. The registry is continuously audited with rigorous quality control. 11 The version used in this study recorded patient listings and follow-up until September 30, 2015. Data included in the UNOS are extracted from the transplant candidate registration form, which is filled at listing; transplant recipient registration form, which is filled at the time of transplantation; and transplant recipient follow-up form, which is filled at follow-up.
Patient Population
We identified all patients ≥18 years of age, listed for HT with a primary diagnosis of myocarditis between January 2000 and September 2015. Additional cases were identified in the diagnosis free text variable. We compared their baseline characteristics, MCS utilization, and post-transplant outcomes to those of patients with ischemic and other nonischemic causes of HF. We excluded patients with congenital, valvular, and restrictive heart disease and those with hypertrophic cardiomyopathy and retransplantation.
Statistical Analyses
All analyses were performed using Statistical Package for Social Sciences (SPSS, version 19.0; SPSS Inc, Chicago, IL). Categorical variables are presented as percentages and compared using Pearson χ 2 test. Continuous variables are presented as mean and SD or median and 25th-75th percentiles, as appropriate. Comparisons were performed using Student t test (2 normal variables), 1-way ANOVA (>2 non-normal variables), Mann-Whitney U test (2 non-normal variables), and Kruskal-Wallis test (>2 non-normal variables), as appropriate. No assumptions were used for missing data. Survival analyses were done using Kaplan-Meier method with log-rank test and adjusted survival using Cox proportional-hazard model. All tests are 2 sided. P<0.05 is considered statistically significant. Institutional review board approval was not required because only deidentified data sets were used for this analysis.
Results
Demographic Characteristics
Of the 45 941 adults listed for orthotopic heart transplantation (OHT) from 2000 to 2015, we identified 299 patients (0.7%) with a diagnosis of myocarditis and compared them with 15 321 patients with NICM, and 16 686 with ischemic cardiomyopathy (ICM ; Table) .
Patients Out of 68 patients with myocarditis and biventricular support (biventricular MCS or ECMO), 46 patients (68%) were listed as status 1A compared with 31.1% without biventricular support at listing (P<0.001). However, patients with myocarditis without biventricular support still were more likely to be listed as 1A than those with other HF types (myocarditis 31% versus NICM 21% versus ICM 21%; P<0.001).
Wait List Outcomes
Of 299 myocarditis patients, 194 patients (65%) received OHT, 32 patients (11%) died while waiting, 17 patients (6%) were delisted for deterioration, 23 patients (8%) were delisted for improvement, 18 patients (6%) had other or unknown outcomes, and 15 patients (5%) remained on the wait list. Patients with myocarditis spent less time on the waitlist (myocarditis 2.0 months versus NICM 4.2 months versus ICM 4.2 months; P<0.001).
There were no differences in wait-list mortality or delisting between sexes (log rank P=0. 22 
Mechanical Circulatory Support
Overall, 33% of myocarditis patients required MCS (left ventricular assist device, biventricular assist devices, or total artificial heart), compared with 17.5% of NICM and 17.1% of ICM patients; P<0.001). Isolated left ventricular assist device use was less common in myocarditis (myocarditis 15.2% versus NICM 16.9% versus ICM 16.5%), whereas biventricular support (biventricular assist devices or total artificial heart) use was more often required in myocarditis patients than in those with NICM and ICM (20.2% versus 2% versus 1.8%; P<0.001). The use of intra-aortic balloon pump (myocarditis 9.0% versus NICM 4.7% versus ICM 6.5%; P<0.001) and ECMO (myocarditis 4.7% versus NICM 0.4% versus ICM 0.8%; P<0.001) were also more frequent (Table) .
Heart Transplantation Outcomes
Recipients with diagnosis of myocarditis had significantly higher panel-reactive antibodies than ICM and NICM patients (P<0.001) but similar Human Leukocyte Antigen mismatch (P=0.085). Rejection rates were comparable before discharge (myocarditis 9.5% versus NICM 9.7% versus ICM 8.9%; P=0.039) and at 1 year (myocarditis 24.4% versus NICM 26.4% versus ICM 23.9%; P=0.002; Table) .
One-, 5-, and 15-year survival was 89%, 78%, and 56% for patients with myocarditis, compared with 90%, 77%, and 44% for those with NICM (P=0.62) and 88%, 74%, and 31% for patients with ICM (P=0.061; Figure 2) .
Retransplantation rates were similar between myocarditis and NICM (log rank P=0.71) and ICM (log rank P=0.12). 
Discussion
In this study, we report the largest contemporary cohort of patients listed for OHT with the diagnosis of myocarditis, unveiling new findings and confirming previous knowledge regarding this unique population. Heart Transplantation in Adults With Myocarditis We found that myocarditis accounts for <1% of patients who receive heart transplantation, which is consistent with previous estimates in the literature of 1% to 8%. 7 However, our report indicates that patients with myocarditis have unique characteristics that distinguish them from other advanced HF patients. For example, we show that advanced HF from myocarditis occurs mostly in young male patients. These age and sex differences are consistent with previous reports, where myocarditis has been shown to affect younger patients [12] [13] [14] and to be linked to male sex hormones. 6, 15 The diagnosis of myocarditis was associated with higher acuity at listing, evidenced by a 10-fold higher requirement for biventricular MCS, 5-fold higher requirement for ECMO, and 3-fold higher requirement for ventilator need. Accordingly, myocarditis patients were more frequently listed as status 1A with less time for optimization of heart failure therapy and implantable cardioverterdefibrillators placement. Our data confirm that myocarditis affects both ventricles, 14, 16 and therefore, patients require uni-and biventricular MCS more frequently, 17 similar to toxic cardiomyopathies, such as chemotherapy-induced cardiomyopathy. 18 We also describe the natural history of myocarditis patients in the transplant waitlist and confirm a higher likelihood of recovery. 12, 16 In our series, ≈7% of listed patients were delisted for recovery, twice as much as other HF types. This suggests that it is essential that patients with myocarditis-especially those with durable MCS-be monitored closely for signs of recovery, possibly by using intensified weaning protocols, even after listing for OHT. It is important to note, however, that the natural history is different among different types of myocarditis. For example, patients with giant cell myocarditis have been shown to have low recovery rates and most will have progressive disease requiring advanced therapies. 19 We also investigated transplantation outcomes in myocarditis patients, which historically has been controversial because of fears of increased rejection and death after transplantation. In fact, some small studies have reported ≤2.2-fold increased risk of rejection and lower 1 year survival (58% versus 82%) compared with age-and sex-matched controls. 7, 20 Previously, O'Connell et al 21 queried the UNOS database from 1968 to 1993 and reported the outcomes of 142 myocarditis patients to be similar to that of patients with other HF types. Similarly, a recently published single-center, retrospective experience concluded that patients with myocarditis had survival comparable to patients transplanted for other indications. 8 In this study, we confirm that patients with myocarditis have post-transplant survival similar to other HF patients, despite being younger and having higher panel-reactive antibodies, both well-established predictors of poorer survival. 22 These reports also suggest that MCS with durable ventricular assist devices may provide a good alternative to transplantation in patients with acute myocarditis, especially in view of higher rates of recovery compared with other cardiomyopathies. However, careful assessment of right ventricular function is crucial when patients with myocarditis are considered for durable MCS, especially given the high rates of right ventricular support utilization in this series. Because the data presented here are obtained from a transplantation database, little is known about the outcomes of continuous-flow MCS in patients with myocarditis, and future studies from larger MCS registries may provide more granular information with regard to recovery and outcomes. 
Limitations
We acknowledge multiple limitations of this study. In general, registries provide large numbers of patients at the expense of accuracy and granularity. Therefore, data accuracy is unverifiable and of poorer quality than data derived from prospective studies. As a result, one of the main limitations of this report concerns the accuracy of the diagnosis of myocarditis. Because the registry does not offer biopsy information, we cannot be sure of how many of these cases were confirmed by histology and had de facto myocarditis, although myocarditis can be diagnosed based on clinical criteria. 3 Additionally, because the clinicians reporting to UNOS are highly trained heart failure and transplant specialists, it is likely that the accuracy of this diagnosis is higher than that in the real-world scenario. Also, because most transplant centers are highly proficient in endomyocardial biopsies, it is possible that a considerable number of these diagnoses were indeed based on histology. Finally, we speculate that given the multitude of putative HF diagnoses in the UNOS reporting form, it is likely that clinicians would only choose the diagnosis of myocarditis when there was a fair amount of diagnostic certainty. More pertinent, perhaps, is the fact that the diagnosis of myocarditis may have been severely underestimated because many patients with dilated cardiomyopathies may have had unrecognized myocarditis.
The retrospective nature of this study predisposes to biases and confounding factors that statistical adjustments cannot completely avoid. For example, we cannot draw inferences on the natural history of all patients with myocarditis, but only those sick enough to require listing for transplantation, introducing significant referral bias. Because this database cannot provide clinical granularity, little insight is possible into treatment or diagnostic modalities used in these patients. Similarly, because there is no information pertaining to the pathogenesis of myocarditis, we cannot make inferences on treatment, presentation, or outcomes of different types of myocarditis. In addition, because UNOS reporting contains the diagnosis of viral cardiomyopathy, it is possible that some myocarditis could have been interchangeably reported as viral cardiomyopathy and vice versa. Finally, there are limited data on rejection and late transplant outcomes, including types or grades of rejection and cardiac allograft vasculopathy. This may be especially relevant considering that transplanted myocarditis patients have been reported to have increased frequency of late acute cellular rejection 8 but not cardiac allograft vasculopathy. 
Conclusions
Patients listed for OHT with a diagnosis of myocarditis are younger, present more acutely, and recover more frequently but require more uni-and biventricular MCS. Despite higher allosensitization, heart transplantation rejection and survival are similar to that of patients with other types of HF.
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